AI Solution Supporting Wins Best New Radiology Solution Award
By Medimaging International staff writers
Posted on 18 Sep 2019
Image: The ProFound AI for DBT has been selected as the winner of the “Best New Radiology Solution” Award in the 2019 MedTech Breakthrough Awards program (Photo courtesy of iCAD).
An FDA-cleared artificial intelligence (AI) solution that supports breast cancer detection in 3D tomosynthesis has been selected as the winner of “Best New Radiology Solution” Award in the 2019 MedTech Breakthrough Awards program.
ProFound AI for Digital Breast Tomosynthesis (DBT) from iCAD Inc (Nashua, NH, USA) is the first and only US FDA-cleared AI solution that supports breast cancer detection in DBT, or 3D mammography. The technology is intended for use concurrently by radiologists reading DBT exams and uses a cutting-edge algorithm developed with the latest in deep learning.
Trained to detect malignant soft-tissue densities and calcifications, ProFound AI aids radiologists in breast cancer detection and is clinically proven to improve cancer detection rates, reduce false positives and unnecessary patient recalls, and decrease reading times for radiologists. The software rapidly and accurately analyzes each DBT image and provides radiologists with key information, such as Certainty of Finding and Case Scores, which assist radiologists in making clinical decisions and prioritizing caseloads.
ProFound AI for DBT runs on the PowerLook platform with NVIDIA graphical processing units (GPU). PowerLook is a ﬂexible and reliable DICOM platform that easily integrates with image modalities, mammography review workstations, picture archiving and communication systems (PACS) and image storage systems. Leveraging the latest in GPU technology, the algorithm can rapidly process a four-view tomosynthesis case, ensuring results are available to radiologists in the most efficient manner.
“iCAD is a previous MedTech Breakthrough Award winner, and we are delighted to see the company continue to innovate. ProFound AI is a revolutionary technology built on the latest deep-learning and artificial intelligence technology that assists radiologists and addresses the challenges of reading breast tomosynthesis cases,” said James Johnson, managing director, MedTech Breakthrough. “We extend a hearty congratulations to the entire iCAD team on their innovative spirit and ability to execute on incorporating sophisticated AI technology in a platform that delivers incredibly real-world benefits.”